DULOXETINE CAPSULE (DELAYED RELEASE)

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

DULOXETINE (DULOXETINE HYDROCHLORIDE)

থেকে পাওয়া:

ALTAMED PHARMA

এটিসি কোড:

N06AX21

INN (আন্তর্জাতিক নাম):

DULOXETINE

ডোজ:

60MG

ফার্মাসিউটিকাল ফর্ম:

CAPSULE (DELAYED RELEASE)

রচনা:

DULOXETINE (DULOXETINE HYDROCHLORIDE) 60MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

30/100/1000

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0152350002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2023-02-06

পণ্য বৈশিষ্ট্য

______________________________________________________________________________
_Duloxetine Product Monograph_
_ Page 1 of 82_
PRODUCT MONOGRAPH
PR DULOXETINE
Duloxetine Delayed-Release Capsules
Duloxetine (as duloxetine hydrochloride)
30 mg and 60 mg
Manufacturer’s standard
ANALGESIC/ANTIDEPRESSANT/ANXIOLYTIC
Altamed Pharma
1565, boul. Lionel-Boulet
Varennes, Quebec
J3X 1P7
Submission Control No.: 271223
DATE OF REVISION:
FEB
06,
2023
______________________________________________________________________________
_Duloxetine Product Monograph_
_ Page 2 of 82_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT
INFORMATION......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
5
WARNINGS AND PRECAUTIONS
...............................................................................
6
ADVERSE REACTIONS
................................................................................................
18
DRUG INTERACTIONS
................................................................................................
37
DOSAGE AND ADMINISTRATION
............................................................................
40
OVERDOSAGE
..............................................................................................................
43
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 44
STORAGE AND STABILITY
........................................................................................
47
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................ 47
PART II: SCIENTIFIC INFORMATION
..............................................................................
49
PHARMACEUTICAL INFORMATION
..............................